Background: Patients with stage III non-small-cell lung cancer (NSCLC) and limited disease small-cell lung cancer are excluded from concurrent chemoradiation mostly on the basis of comorbidity and age. The purpose of this prospective study was to get insight in what proportion of patients with locally advanced lung cancer would be suitable for concurrent chemoradiation.
introduction
Several randomized clinical trials as well as meta-analyses have established that the best survival can be achieved in patients with locally advanced (stage III) non-small-cell lung cancer (NSCLC) and limited disease small-cell lung cancer (LD-SCLC) with concurrent chemoradiation instead of the sequential approach [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] . This is reflected in guidelines for standard practice [13] [14] [15] . However, due to the higher toxicity of concurrent treatment, this is generally only given to patients with minimal or no comorbidities, a good general condition, and who are relatively young. For example, in the meta-analysis on concurrent versus sequential chemoradiation in NSCLC, the majority of patients was <65 years (only 16% was 70 or older), nearly no patients had a World Health Organization (WHO) performance status (PS) of two, and none had a PS below two [7] .
Comorbidity is frequently observed in elderly patients and in smokers, two groups with a high incidence of lung cancer [16] [17] [18] [19] [20] [21] [22] . These patients often receive less aggressive treatment [16, 19, 20] and are vastly underrepresented in clinical trials.
The aim of this study was to evaluate what proportion of patients would be suitable for concurrent chemoradiation on the basis of a priori criteria. In order to avoid selection bias as much as possible, we report on a population-based study that 
maastricht cancer registry
The MCR is a population-based cancer registry, which was established in 1984 and is a department of the Comprehensive Cancer Centre Limburg (IKL). The MCR covers the region of mid-and southern Limburg, which is situated in the southeast of The Netherlands. On 1 January 2006, the region covered a total of 853 553 inhabitants. The main sources of information are regional hospitals and pathology laboratories from which the MCR receives reports on a weekly basis since 1986. After receiving the notification reports, trained registration clerks collect all relevant data of the patients and tumors from the medical records. Information on topography and morphology was coded according to the International Classification of Diseases for Oncology [23] . Tumor stage was recorded in accordance with the tumour-node-metastasis classification system [24] .
Completeness of case ascertainment of the MCR is very high; for lung cancer, this is estimated to be >95% [25] .
scoring of comorbidity
Comorbidity of all lung cancer patients was scored using a slightly adapted version of the Charlson comorbidity index (CCI) [26] , as depicted in Table 1 . The data were extracted from previous admissions, letters from and to other specialists, medical history, and preoperative screening. Comorbidity was defined as disease that was present at the time of diagnosis.
In this study, only patients with important comorbidities were labeled as having a comorbidity (Table 1) . From 25 patients, comorbidity could not be retrieved. Analysis was carried out on the 686 patients with known comorbidity status.
eligibility for concurrent chemoradiation
On the basis of the inclusion criteria of key phase III trials involving concurrent chemoradiation [2] [3] [4] [5] [6] [7] [8] [9] , current American College of Chest Physicians and National Institute for Health and Clinical Excellence guidelines [13] [14] [15] , and the ongoing major phase III trial RTOG 0617/ NCCTG N0628/CALGB 3060 [27] , we chose the worst inclusion parameters in these representative studies. These were age at maximum 74 years, WHO PS at maximum two, weight loss <10% in the last 3 months, Forced expiratory volume (FEV1) at 1 second at least 40% of the age-predicted value, and adequate cardiac, renal and hematological functions. As WHO PS and CCI are closely related [28] , we restricted eligibility for concurrent chemoradiation in this series to patients <75 years old or one or more important comorbidities on the CCI. Other inclusion parameters that could influence the selection for high-dose radiation like the size of the radiation field and hence the volume of healthy lung to be irradiated were not taken into account.
statistical analysis
Descriptive statistics were used as indicated in the text. To compute significance between groups, the chi-square test was used. P values <0.05 were considered significant. comorbidities From the 686 patients with known comorbidity status, patients <75 years had significantly less important comorbidities than older patients (47.1% versus 63.1% respectively; P = 0.001) (Figure 1 ). Of the 526 patients <75 years, comorbidities were as follows: 278 (52.9%) 0, 188 (35.7%) 1, and 56 (11.4%) 2 or more. As expected, lung diseases and cardiovascular disorders represented the overwhelming proportion of comorbidities in both genders (Tables 4 and 5 ). 
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No significant differences in the incidence of comorbidities were observed between NSCLC and SCLC patients (287 of 555, 51.7% versus 62 of 131, 47.3%; P = 0.35) (Tables 2 and 3 ). In the age group <75 years, males had significantly more comorbidities than females (190 of 362, 52.5% versus 58 of 164, 35.4%, respectively; P = 0.0003) ( Tables 2 and 3 ).
eligibility for concurrent chemoradiation
As depicted in Figures 2 and 3 , a decreasing number and proportion of patients were considered as being eligible for concurrent chemoradiation with increasing age. In the age group of 60-69, only 50% of the patients were eligible for concurrent chemoradiotherapy. In the age 70-74 years, less than half were suitable for aggressive therapy. However, already 23.3% of the patients were 75 years or older, excluding them directly for concurrent chemotherapy and radiotherapy. As a result, 408 of 686 (59%) of the whole patient group was considered as ineligible for concurrent chemoradiation.
discussion
Concurrent chemoradiation is at present the treatment of choice for patients with locally advanced NSCLC and LD-SCLC [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] . However, due to its higher toxicity, this combination is mostly restricted to patients in a good general condition, minimal comorbidity and who are relatively young [7, [13] [14] [15] . Although other groups have reported on the incidence of comorbidity, PS and its impact on treatment of lung cancer patients [16] [17] [18] [19] [20] [21] [22] [28] [29] [30] , to the best of our knowledge, no population-based study has investigated which proportion of patients would be eligible for concurrent chemotherapy and radiotherapy.
In this prospective, population-based study, more than half of the patients with stage III NSCLC or LD-SCLC were not eligible for concurrent chemoradiation on the basis of criteria of age and important comorbidities that were present at diagnosis. About one-fourth was 75 years or older, and of the younger group, only 53% had no comorbidity. Comorbidity was as expected composed of lung diseases (mainly chronic obstructive pulmonary disease (COPD) and cardiovascular disorders.
Some potential caveats of this study should be discussed. First, the a priori criterion of one or more significant comorbidity to exclude patients for concurrent chemoradiation may be too wide. A considerable proportion of patients with lung cancer and COPD or cardiovascular diseases may still be eligible for concurrent chemoradiotherapy. Functional criteria like lung function and exercise capacity were unfortunately not available from the datasets. However, solely on the basis of the existence of COPD, patients should not a priori be excluded from potentially curative therapy. Also for cardiovascular disease, the presence of this comorbidity as such should not exclude patients for high-dose chemoradiation. Exercise tolerance, and on indication electrocardiography and cardiac ultrasound, may give more insight on the potential eligibility for aggressive therapy. A simple functional test like the 6-min walking distance may be a pragmatic, but at present unproven, method to get more insight in the functional status of the patient and hence its tolerance for concurrent chemoradiation than comorbidity on itself. Second, the incidence of comorbidities could be overestimated. However, as only selected comorbidities were used, and not the full CCI items, the real incidence of all comorbidity may be higher [18] . Third, although the PS was not determined, we believe that as PS and comorbidity are strongly correlated [28] , our results are still valuable. Moreover, it has been shown that comorbidity influences significantly treatment choices, underlining its clinical usefulness [29, 30] .
Fourth, we selected patients suitable for concurrent treatment also on the basis of age, being <75 and the presence of at maximum one important comorbidity. Weight loss was not taken into account because it was not scored prospectively. Also the size of the radiation field and the related irradiated lung volume (e.g. the mean lung dose or the volume of the lungs receiving >20 Gy, i.e. the V 20 ) was not considered. This represents eligibility criteria for concurrent chemoradiation that are probably very close to those of important phase III studies and advocated by guidelines [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] 27] . We therefore believe that our figures are not only representative for the general population in the MCR region but also reflect realistic inclusion criteria for aggressive treatment. However, with the rising numbers of patients >75 years without significant comorbidities, the exclusion of patients for concurrent chemoradiation should clearly be reconsidered [31] .
In spite of that we found that only 41% of the patients with stage III lung cancer would be suitable for concurrent chemoradiation.
This finding has important implications. First, it should be investigated to what extend patients with given comorbidities and/or advanced age are suitable for concurrent chemoradiation. Indeed, the patient population that is in reality included in trials is younger and healthier than the eligibility criteria of studies allow [7] . As a consequence, only sparse data on the outcome of elderly patients and those with comorbidity are available. It may be possible that provided adequate supportive care could be given, they would be suitable for more aggressive but also more efficacious combination treatment. Ultimately, this should be reflected in clinical guidelines. Secondly, the development of less toxic but still curative treatments for individuals that cannot tolerate concurrent therapy should be a priority in view of the large number of patients that fall in this category. Sequential chemotherapy and high-dose radiotherapy may be a somewhat less, but still valuable alternative for patients who are not eligible for Annals of Oncology original article concurrent chemotherapy and radiation [2] [3] [4] [5] [6] [7] . Personalized radiotherapy [32] , the use of charged particle radiation [33] , and the combination of radiation with targeted agents [34] are some of the other possibilities.
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